Surrey on some epidemiological factors of cutaneous leishmaniasis in Fars Province of Iran  by Fakoorziba, M.R. et al.
1T
F
S
D
T
R
A
m
M
o
p
c
s
w
f
t
s
c
H
e
1
t
2
r
d
i
e
w
c
o
i
e
u
1
hInternational Journal of Infectious Diseases 16S (2012) e158–e316
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
journa l homepage: www.e lsev ier .com/ locate / i j id5th International Congress on Infectious Diseases (ICID) Abstractsype: Poster Presentation
inal Abstract Number: 42.017
ession: Parasitology & Parasitic Infections
ate: Thursday, June 14, 2012
ime: 12:45-14:15
oom: Poster & Exhibition Area
meta analysis on artemether in the prevention of Schistoso-
iasis
. Llanto, M.A. Estur ∗, C. Penalosa
Philippine General Hospital, Ermita, Philippines
Background: Schistosomiasis ranks second to malaria in terms
f socioeconomic&publichealth importance,with200millionpeo-
le infected in 75 countries. Praziquantel is the current drug of
hoice and is highly effective against the adult stages of all human
chistosome species. Development of resistance to Praziquantel
as noted. Artemether has been developed as a prophylactic agent
or the prevention of schistosome infections. In this light,we aimed
o evaluate the efﬁcacy of artemether in the prevention of schisto-
omiasis.
Methods:Wesearched Pubmed, Google Scholar for randomized
ontrolled trials. 6 studies fulﬁlled the inclusioncriteria for analysis.
owever, we were only able to retrieve the full text of 2 articles
xamined through meta analysis. Searched trials published from
995 to 2011.
Eligible studies were randomized and blinded, placebo con-
rolled trials of oral artemether at a dose of 6mg/kg once every
-4 weeks with participants’ ages ranged from 5-60 years old,
egardless of sex. Trials that compared artemether with another
rug (praziquantel) and trials that combined artemetherwith praz-
quantel were excluded.
Cochrane Collaboration’s tool for assessing risk of bias was
mployed to ensure the validity of the selected studies. Results
ere extracted independently by two authors using a paper data
ollection formand any disagreementswere resolved by consensus
f the three authors.
Three investigators carried out the initial search and two
nvestigators independently reviewed studies. Our indices for het-
rogeneity were the p value (<0.00001) and I2 (97%). Analysis done
sing the Review Manager v5.1.
201-9712/$36.00
ttp://dx.doi.org/10.1016/j.ijid.2012.05.004Results: Two eligible studies were analyzed. Among the 529
participants who were treated with artemether, there were 79
incurred schistosomiasis infection. In the placebo group, 153 out
of 511 were found to be infected with schistosomiasis (Risk
ratio =0.50 [at 95% CI =0.40, 0.61]).
Conclusion: This study shows that repeated oral artemether
signiﬁcantly reduces incidence and intensity of patent schistosomi-
asisinfection and results in high compliance. Hence it can be used
as a preventive tool for the control of this parasitic disease and
may be included in the integrated schistosomiasis control efforts.
Moremethodologically sound studies investigating theefﬁcacyand
safety of Artemether is warranted.
http://dx.doi.org/10.1016/j.ijid.2012.05.688
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Surrey on some epidemiological factors of cutaneous leishma-
niasis in Fars Province of Iran
M.R. Fakoorziba1,∗, F. Eghbal2, H. Eghbal3
1 Shiraz University of Medical Sciences, Shiraz, Fars, Iran, Islamic
Republic of
2 Islamic Azad University, Kazerun Branch, Shiraz, Fars, Iran, Islamic
Republic of
3 Shiraz University of Medical Sciences, Shiraz, Iran, Islamic Republic
of
Background: Cutaneous leishmaniasisis a common health
problem in tropical and subtropical areas and about 10-50 million
people are involved in the world. WHO has estimated that about
1.5 million new cases of Cutaneous and Visceral leishmaniasis are
appearing in the world annually. This disease is endemic in about
80 countries and its prevalence is more obvious in Iran and Saudi
Arabia.
Methods: Information was collected from center of disease
control (CDC) of the endemic area for getting information about
some epidemiological factors such as sex, age, season, site of body
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nvolvement, interval between appearance of lesions and diagnosis
nd number of cutaneous lesions in each affected person.
Results: Results showed that cutaneous leishmaniasis was
bserved more in children younger than 15 years-old.
Although, 44.9% of all patients were females and 51.1% were
ales but sex factor of the patients was not statistically signiﬁcant.
his investigation demonstrated that 44.4% had only one lesion.
ore than one skin lesion reported in 55.6% of the patients that is
ndicated that sand- ﬂy, for complete feeding, bites it’s host more
han one time or more than one sand ﬂy bite patients.
Conclusion: In order to prevention of leishmaniasis, health edu-
ation about this disease and also providing protection facilities are
ecommended in endemic areas.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.689
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odeling and simulation to evaluate pyronaridine exposure in
ediatric malaria patients
. Fleckenstein1,∗, J. Methaneethorn1, S. Duparc2, I. Borghini-
uhrer2, C.-S. Shin3, D. Jung4
University of Iowa, Iowa City, IA, USA
Medicines for Malaria Venture, Geneva, Switzerland
Shin Poong Pharmaceuticals, Seoul, Korea, Republic of
Pharmaceutical Research Services, Cupertino, CA, USA
Background: Malaria causes substantial illness and death in
he world’s population, especially in children less than 5 years
ld. Pyronaridine/Artesunate (PA) 3:1 ﬁxed dose combination is
novel artemisinin combination therapy (ACT) in development
or the treatment of acute uncomplicated Plasmodium falciparum
nd blood stage of P. vivax malaria. Tablet (180:60mg PA) and
ediatric granule (60:20mg PA) formulations are under parallel
evelopment for clinical use. The purpose of this study is to use
harmacokinetic modeling and simulation to explore exposure
mong pediatric dosing groups for 3 PA dosing regimens.
Methods: Population pharmacokinetics of pyronaridine was
onducted using non-linear mixed effect modeling. The pharma-
okinetic model incorporated data from healthy (166) and malaria
nfected (642) subjectsparticipating inninePhase I-III clinical trials.
ge ranged from 0.6 to 60 years and weight from 9 to 90.1 kg. Inﬂu-
nces of age, weight, bodymass index,malaria infection, creatinine
learance, alanine aminotransferase, aspartate aminotransferase,
ender, and ritonavir administration on pyronaridine pharmacoki-
etics were evaluated. Monte Carlo simulations were performed to
eﬂect pyronaridine exposure in pediatric malaria patients based
ncurrentdosing recommendations. Typical pyronaridineAUCval-
es expected for pediatric malaria patients of weights between
-20kg were obtained using covariate parameter relationship of
he ﬁnal model and the current dosage recommendations.
Results: Pyronaridine pharmacokinetics was best described by
two-compartment model with ﬁrst order absorption and elim-
nation from the central compartment. Signiﬁcant covariates on
yronaridinepharmacokinetics includedweight on apparent clear-
nce (CL/F), apparent central volume of distribution (V2/F), and
pparent peripheral volume of distribution (V3/F) and malaria
nfection on CL/F, and V2/F. Pyronaridine exposures for pediatricfectious Diseases 16S (2012) e158–e316 e159
malaria patients are shown for 3 PAweight-based dosing regimens.
Figure. Box-plot depicting number of sachets and Ln(AUC)
distribution of pyronaridine based on current dosing recom-
mendations for pediatric malaria patients; bars represent 25th
and 75th percentiles; whiskers represent 10th and 90th per-
centiles.
Conclusion: These results suggest that the use of PK model-
ing and simulation with adult and pediatric data can be used to
select appropriate dosing regimens in children. Simulations were
conducted using population pharmacokinetic modeling to show
weight-based dosing produces consistent pyronaridine exposure
among dosing groups in pediatric malaria patients between 5 and
20kg and drug exposures that are similar to those achieved in
adults.
http://dx.doi.org/10.1016/j.ijid.2012.05.690
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Clinical presentations of ALA (amoebic liver abscess) among
tuak consumers in Medan
F. Ginting
Faculty of Medicine University of Sumatera Utara/Adam Malik Central
Hospital, Medan, Indonesia
Background: Amoebiasis is endemic in many tropical countries
including Indoensia. Amoebic liver abscess (ALA) is one of the most
important extraintestinal amoebiasis, which alcoholism is one of
the risk factors. Tuak is a traditional beverage contains 15 – 25%
alcohol inMedan. The presentation of amoebic liver abscess among
tuak consumers in Medan has not been studied.
Objective: To describe the presentation of ALA among tuak con-
sumers in Medan.
Methods: This is an observational study conducted from May
2007 to March 2012 and included all of the patients with amoe-
bic liver abscess. The diagnosis of liver abscess was based on the
clinical appearances and USG. The presentations of ALA which
were recorded include fever, leucocytosis, and hepatomegaly. The
abscess puncture was performed for etiology conﬁrmation. All of
the patients received metronidazole and paramomycin. We per-
